Showing 1971-1980 of 4274 results for "".
- Sentient Adds to C-Suitehttps://modernaesthetics.com/news/sentient-adds-to-c-suite/2473510/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, wh
- FDA Grants 510(k) Clearance to Venus the Versa Pro Systemhttps://modernaesthetics.com/news/fda-grants-510k-clearance-to-venus-the-versa-pro-system/2473495/The U.S. Food and Drug Administration has granted marketing clearance to Venus Concept Inc.’s Venus Versa Pro System. Venus Versa is customizable and upgradable and supports 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF tec
- Estée Lauder, Manchester United Partner to Boost Fans’ Skin Healthhttps://modernaesthetics.com/news/estee-lauder-manchester-united-partner-to-boost-fans-skin-health/2473451/Estée Lauder will team up with Manchester United, to reach and engage their extensive fanbase in China and the Asia Pacific region. Kicking off in Summer 2023, the partnership’s inaugural campaign will launch with players from Manchester United’s first team, inc
- LASEROPTEK Co. Ltd. Taps Dr. Neil Shah as New KOLhttps://modernaesthetics.com/news/laseroptek-co-ltd-taps-dr-neil-shah-as-new-kol/2473433/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Exosome News: Elevai Labs Scores Grant to Better Characterize Stem Cell-derived Exosomeshttps://modernaesthetics.com/news/elevai-labs-scores-grant-to-better-characterize-stem-cell-derived-exosomes/2473403/Elevai Labs is partnering with Dr. Stanislav Sokolenko’s Lab at Dalhousie University in Nova Scotia, Canada to better characterize Elevai 's stem cell-derived exosomes thanks to a non-repayable grant from the Mitacs Accelerate Grants Program (“Mitacs”).
- Hydrafacial X Omorovicza Announce Launch of Advanced Skin Renewal Boosterhttps://modernaesthetics.com/news/hydrafacial-x-omorovicza-announce-launch-of-advanced-skin-renewal-booster/2473364/The Beauty Health Company’s Hydrafacial is rolling out a new booster co-created with Hungarian skincare brand Omorovicza. The booster, available immediately to Hydrafacial providers in North America and EMEA, leverages Omorovicza’s patented Healing Concentrate for a mo
- Bausch Health Suspends Plans for Solta IPOhttps://modernaesthetics.com/news/bausch-health-suspends-plans-for-solta-ipo-1/2473255/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- Suneva's Silhouette InstaLift Recognized with New Beauty Awardhttps://modernaesthetics.com/news/sunevas-silhouette-instalift-recognized-with-new-beauty-award/2473219/Suneva Medical, Inc.'s non-surgical thread lift, Silhouette InstaLift®, is the Best Thread Lift Treatment in NewBeauty's 2022 Beauty Awards. It uses collagen-stimulating absorbable sutures that offer patients immediate and lasting results with minimal recovery time.
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Business News: Solta Medical Readies for IPOhttps://modernaesthetics.com/news/business-news-solta-medical-readies-for-ipo/2473195/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.